Amirali Talasaz Sells 116,972 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 116,972 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $150.79, for a total value of $17,638,207.88. Following the completion of the transaction, the chief executive officer owned 1,881,336 shares in the company, valued at approximately $283,686,655.44. This trade represents a 5.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The shares were sold at an average price of $109.89, for a total transaction of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The shares were sold at an average price of $100.32, for a total transaction of $5,016,000.00.

Guardant Health Stock Up 13.8%

GH opened at $170.77 on Thursday. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $172.61. The company has a 50 day moving average of $116.77 and a two-hundred day moving average of $105.20. The company has a market cap of $22.64 billion, a P/E ratio of -50.37 and a beta of 1.59.

Institutional Investors Weigh In On Guardant Health

A number of large investors have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new position in Guardant Health in the 4th quarter worth $27,000. Chesapeake Asset Management LLC purchased a new position in Guardant Health in the 4th quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health during the fourth quarter valued at about $35,000. Finally, Parallel Advisors LLC increased its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on GH. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Royal Bank Of Canada assumed coverage on Guardant Health in a research note on Thursday, June 11th. They set an “outperform” rating and a $185.00 price objective on the stock. Wolfe Research began coverage on Guardant Health in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 target price for the company. Piper Sandler set a $127.00 target price on Guardant Health in a research note on Thursday, May 21st. Finally, BTIG Research raised their target price on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of “Buy” and an average target price of $146.18.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.